Rodriguez Erika F, Reynolds Jordan P, Jenkins Sarah M, Winter Stephanie M, Henry Michael R, Nassar Aziza
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA.
Int J Clin Exp Pathol. 2012;5(5):428-35. Epub 2012 May 23.
Atypical squamous cells of undetermined significance (ASC-US) is a broad diagnostic category that could be attributed to human papillomavirus infection (HPV), malignant neoplasia and reactive conditions. We evaluated our institutional experience with ASC-US in women who are positive for high risk HPV (HRHPV+) by the Digene hybrid capture method from 2005-2009 to identify the risk of progression to squamous intraepithelial lesion (SIL) and cervical intraepithelial neoplasia (CIN) in association with age. We reviewed cytologic and follow-up surgical pathology reports for all specimens available. Progression was defined as a diagnosis of at least CINI on follow-up biopsy or resection or SIL on cytology. We identified 2613 cases and follow-up was available in 1839 (70.4%). Of these 74.2% had just one follow-up, 16.2% had a total of 2 follow-ups, 5.3% had a total of 3 follow-ups, and the remaining had as many as 6 follow-ups. Among the 1839 patients, 69.4% were age 30 or younger, 16.0% were between 31 to 40, 9.0% were between 41 to 50, and 5.6% were 51 or older. Among these, 25-30% progressed to dysplasia. The risk of progression varied by age (p=0.04) and was lowest among women between the ages of 41-50. Our findings highlight the importance of continued cytologic follow-up in women with HRHPV+ ASC-US in order to detect progression of disease, although the risk of progression is age dependent.
意义不明确的非典型鳞状细胞(ASC-US)是一个宽泛的诊断类别,可能归因于人类乳头瘤病毒感染(HPV)、恶性肿瘤和反应性病变。我们评估了2005年至2009年期间通过Digene杂交捕获法检测为高危HPV阳性(HRHPV+)的女性ASC-US的机构经验,以确定与年龄相关的进展为鳞状上皮内病变(SIL)和宫颈上皮内瘤变(CIN)的风险。我们回顾了所有可用标本的细胞学和后续手术病理报告。进展定义为随访活检或切除时至少诊断为CINI或细胞学诊断为SIL。我们识别出2613例病例,其中1839例(70.4%)有随访资料。在这些病例中,74.2%仅有一次随访,16.2%共有2次随访,5.3%共有3次随访,其余的有多达6次随访。在1839例患者中,69.4%年龄在30岁及以下,16.0%在31至40岁之间,9.0%在41至50岁之间,5.6%为51岁及以上。其中,25%-30%进展为发育异常。进展风险因年龄而异(p=0.04),在41至50岁的女性中最低。我们的研究结果强调了对HRHPV+ ASC-US女性持续进行细胞学随访以检测疾病进展的重要性,尽管进展风险与年龄有关。